JP2017121233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017121233A5 JP2017121233A5 JP2016232580A JP2016232580A JP2017121233A5 JP 2017121233 A5 JP2017121233 A5 JP 2017121233A5 JP 2016232580 A JP2016232580 A JP 2016232580A JP 2016232580 A JP2016232580 A JP 2016232580A JP 2017121233 A5 JP2017121233 A5 JP 2017121233A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- hsp90 inhibitor
- patient
- hsp90
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 65
- 206010028980 Neoplasm Diseases 0.000 claims 61
- 238000000034 method Methods 0.000 claims 28
- 238000002560 therapeutic procedure Methods 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 19
- 101710113864 Heat shock protein 90 Proteins 0.000 claims 17
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 12
- 210000004881 tumor cell Anatomy 0.000 claims 10
- 230000002601 intratumoral effect Effects 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 5
- SUPVGFZUWFMATN-UHFFFAOYSA-N zelavespib Chemical compound N1=CN=C2N(CCCNC(C)C)C(SC=3C(=CC=4OCOC=4C=3)I)=NC2=C1N SUPVGFZUWFMATN-UHFFFAOYSA-N 0.000 claims 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 4
- 210000004958 brain cell Anatomy 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- 238000001574 biopsy Methods 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000012188 paraffin wax Substances 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- UYODNJZBUUEXPC-UHFFFAOYSA-N 9-[2-(2,2-dimethylpropylamino)ethyl]-8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]purin-6-amine Chemical compound N1=CN=C2N(CCNCC(C)(C)C)C(SC=3C(=CC=4OCOC=4C=3)I)=NC2=C1N UYODNJZBUUEXPC-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 102000001712 STAT5 Transcription Factor Human genes 0.000 claims 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 102000055104 bcl-X Human genes 0.000 claims 1
- 108700000711 bcl-X Proteins 0.000 claims 1
- 230000000711 cancerogenic effect Effects 0.000 claims 1
- 231100000315 carcinogenic Toxicity 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 0 CC(C)(Cc1c2c(*)n[n]1C(/C=C/C(/C(NC)O)=C(\C)/NC(CC1)CCC1[N+]C(Nc1ccc(C(c(c(Oc3c4)c5)ccc5O)(c3ccc4O)O*3=O)c3c1)=S)=C)CC2=O Chemical compound CC(C)(Cc1c2c(*)n[n]1C(/C=C/C(/C(NC)O)=C(\C)/NC(CC1)CCC1[N+]C(Nc1ccc(C(c(c(Oc3c4)c5)ccc5O)(c3ccc4O)O*3=O)c3c1)=S)=C)CC2=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161506010P | 2011-07-08 | 2011-07-08 | |
| US61/506,010 | 2011-07-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014520226A Division JP6054389B2 (ja) | 2011-07-08 | 2012-07-06 | 標識されたｈｓｐ９０阻害剤の使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019125455A Division JP2019194232A (ja) | 2011-07-08 | 2019-07-04 | 標識されたｈｓｐ９０阻害剤の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017121233A JP2017121233A (ja) | 2017-07-13 |
| JP2017121233A5 true JP2017121233A5 (enExample) | 2017-10-12 |
| JP6662759B2 JP6662759B2 (ja) | 2020-03-11 |
Family
ID=47506428
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014520226A Expired - Fee Related JP6054389B2 (ja) | 2011-07-08 | 2012-07-06 | 標識されたｈｓｐ９０阻害剤の使用 |
| JP2014520227A Expired - Fee Related JP6218147B2 (ja) | 2011-07-08 | 2012-07-06 | 標識されたｈｓｐ９０阻害剤の使用 |
| JP2016232580A Expired - Fee Related JP6662759B2 (ja) | 2011-07-08 | 2016-11-30 | 標識されたｈｓｐ９０阻害剤の使用 |
| JP2019125455A Pending JP2019194232A (ja) | 2011-07-08 | 2019-07-04 | 標識されたｈｓｐ９０阻害剤の使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014520226A Expired - Fee Related JP6054389B2 (ja) | 2011-07-08 | 2012-07-06 | 標識されたｈｓｐ９０阻害剤の使用 |
| JP2014520227A Expired - Fee Related JP6218147B2 (ja) | 2011-07-08 | 2012-07-06 | 標識されたｈｓｐ９０阻害剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019125455A Pending JP2019194232A (ja) | 2011-07-08 | 2019-07-04 | 標識されたｈｓｐ９０阻害剤の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20140294725A1 (enExample) |
| EP (3) | EP2729806B1 (enExample) |
| JP (4) | JP6054389B2 (enExample) |
| KR (2) | KR102025142B1 (enExample) |
| CN (3) | CN104081203B (enExample) |
| AU (3) | AU2012282903A1 (enExample) |
| BR (1) | BR112014000445A2 (enExample) |
| CA (2) | CA2841069C (enExample) |
| DK (1) | DK2729806T3 (enExample) |
| EA (1) | EA201490230A1 (enExample) |
| ES (2) | ES2624982T3 (enExample) |
| MX (2) | MX347607B (enExample) |
| WO (2) | WO2013009655A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| EA201490230A1 (ru) | 2011-07-08 | 2014-06-30 | Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч | Применение меченых ингибиторов hsp90 |
| DK2935222T3 (en) | 2012-12-21 | 2019-01-07 | Epizyme Inc | PRMT5 INHIBITORS AND APPLICATIONS THEREOF |
| EP2972394A4 (en) * | 2013-03-15 | 2016-11-02 | Sloan Kettering Inst Cancer | HSP90-DESIGNING AND THERAPY |
| CN103279964B (zh) * | 2013-04-23 | 2015-10-28 | 浙江大学 | 一种基于prca的pet图像动态重建方法及系统 |
| SG11201601542SA (en) | 2013-08-16 | 2016-04-28 | Sloan Kettering Inst Cancer | Selective grp94 inhibitors and uses thereof |
| EP3738594A1 (en) | 2013-09-10 | 2020-11-18 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics having an hsp90 ligand as binding moiety |
| JP6497767B2 (ja) * | 2013-12-16 | 2019-04-10 | 日本化薬株式会社 | 癌治療におけるｈｓｐ９０阻害剤の抗腫瘍効果を予測する方法 |
| WO2015138039A1 (en) * | 2013-12-23 | 2015-09-17 | Memorial Sloan-Kettering Cancer Center | Methods and reagents for radiolabeling |
| EP2942629A1 (en) * | 2014-05-08 | 2015-11-11 | Universität Würzburg | Predictive markers for successful cancer immunotherapy |
| MX387627B (es) | 2014-09-17 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia |
| US20180280397A1 (en) | 2015-10-05 | 2018-10-04 | Memorial Sloan Kettering Cancer Center | Rational combination therapy for the treatment of cancer |
| LT3483164T (lt) | 2017-03-20 | 2020-05-11 | Forma Therapeutics, Inc. | Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai |
| ES2994431T3 (en) | 2017-09-22 | 2025-01-23 | Univ Washington | In situ combinatorial labeling of cellular molecules |
| EP3852791B1 (en) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activating pyruvate kinase r |
| EP3853206B1 (en) | 2018-09-19 | 2024-04-10 | Novo Nordisk Health Care AG | Treating sickle cell disease with a pyruvate kinase r activating compound |
| CN113196055B (zh) | 2018-10-15 | 2025-06-27 | 马克斯·普朗克科学促进协会 | 用于治疗疾病的化合物及其筛选方法 |
| MX2021008984A (es) | 2019-01-30 | 2021-09-08 | Felicamed Biotechnology Co Ltd | Inhibidor jak y metodo de preparacion del mismo. |
| EP3921650A1 (en) | 2019-02-08 | 2021-12-15 | Dewpoint Therapeutics, Inc. | Methods of characterizing condensate-associated characteristics of compounds and uses thereof |
| CA3140651A1 (en) * | 2019-05-15 | 2020-11-19 | Whitehead Institute For Biomedical Research | Methods of characterizing and utilizing agent-condensate interactions |
| CN114729941A (zh) | 2019-09-18 | 2022-07-08 | 露点治疗公司 | 筛选凝聚物相关特异性的方法及其用途 |
| HRP20251148T1 (hr) | 2019-09-19 | 2025-11-21 | Novo Nordisk Health Care Ag | Pripravci koji aktiviraju piruvat-kinazu r (pkr) |
| JP7589935B2 (ja) * | 2019-10-31 | 2024-11-26 | キヤノンメディカルシステムズ株式会社 | 解析装置および解析プログラム |
| US20230357760A1 (en) * | 2020-10-02 | 2023-11-09 | The Trustees Of Dartmouth College | Method and agent for treating/preventing neurodegenerative disease and associated neuroinflammation and for evaluating putative prophylactics/therapeutics for treating/preventing neurodegenerative disease and neuroinflammation |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| CN113025715A (zh) * | 2021-03-23 | 2021-06-25 | 中山大学附属第一医院 | Hop在预测胃癌预后中的应用 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| CN116813622B (zh) * | 2023-05-19 | 2026-02-03 | 中国科学院基础医学与肿瘤研究所(筹) | 一种基于分子伴侣hsp90介导的靶向降解gpx4的嵌合体及其制备方法和应用 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7156111B2 (en) * | 2001-07-16 | 2007-01-02 | Akrion Technologies, Inc | Megasonic cleaning using supersaturated cleaning solution |
| AU2002364566B2 (en) | 2001-12-12 | 2009-03-26 | Conforma Therapeutics Corporation | Assays and implements for determining and modulating HSP90 binding activity |
| US20040121971A1 (en) * | 2002-12-20 | 2004-06-24 | Gang Chen | Therapeutic use of tumor necrosis factor-alpha mutein |
| EP1457499A1 (en) * | 2003-03-12 | 2004-09-15 | Tufts University School Of Medicine | Inhibitors of extracellular Hsp90 |
| US7959915B2 (en) * | 2003-03-12 | 2011-06-14 | Tufts University | Inhibitors of extracellular Hsp90 |
| US20070178537A1 (en) * | 2003-06-30 | 2007-08-02 | Sloan-Kettering Institute For Cancer Research | Assays for detection of bioactive compounds that interact with heat shock protein 90 |
| NZ546044A (en) | 2003-08-29 | 2009-09-25 | Vernalis Cambridge Ltd | Pyrimidothiophene compounds |
| GB0323810D0 (en) | 2003-10-10 | 2003-11-12 | Cancer Rec Tech Ltd | Pyridothiophene compounds |
| CN1922304A (zh) * | 2003-10-31 | 2007-02-28 | 维特克公司 | 用于检测循环肿瘤和内皮细胞的血液测试样机和方法 |
| US9403828B2 (en) * | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| WO2007047955A2 (en) * | 2005-10-21 | 2007-04-26 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
| DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| WO2007139955A2 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| WO2008005937A2 (en) | 2006-06-30 | 2008-01-10 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibiton of hsp90 |
| US8580519B2 (en) * | 2006-11-27 | 2013-11-12 | University Of Maryland, Baltimore | Use of plasma HSP90 related to malignancy |
| WO2008073915A2 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
| AU2008240209A1 (en) * | 2007-04-13 | 2008-10-23 | Pharmacyclics, Inc. | Calcium flux as a pharmacoefficacy biomarker for inhibitors of histone deacetylase |
| JP2011501731A (ja) | 2007-09-10 | 2011-01-13 | ユニバーシティ オブ マサチューセッツ | ミトコンドリア標的化抗腫瘍剤 |
| US20100215575A1 (en) * | 2007-10-12 | 2010-08-26 | Transmolecular, Inc. | Systemic Administration of Chlorotoxin Agents for the Diagnosis and Treatment of Tumors |
| RU2010128107A (ru) * | 2007-12-07 | 2012-01-20 | Байпар Сайенсиз, Инк. (Us) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp |
| EP2274617A4 (en) * | 2008-04-10 | 2011-11-09 | Massachusetts Inst Technology | METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS |
| CN102216775B (zh) * | 2008-08-18 | 2014-04-16 | 马克斯·普朗克科学促进协会 | 对hsp90-抑制剂的易感性 |
| NZ713361A (en) * | 2009-08-17 | 2017-06-30 | Memorial Sloan Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
| JP5941407B2 (ja) * | 2009-10-07 | 2016-06-29 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０阻害剤 |
| AU2010319322A1 (en) * | 2009-11-13 | 2012-05-31 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| CN103596955B (zh) | 2011-04-05 | 2016-11-16 | 索隆-基特林癌症研究协会 | Hsp90抑制剂 |
| JP6266506B2 (ja) * | 2011-04-05 | 2018-01-24 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０阻害物質 |
| BR112013027448A2 (pt) | 2011-04-28 | 2020-09-01 | Sloan-Kettering Institute For Cancer Research | terapia de combinação com hsp90 |
| EA201490230A1 (ru) | 2011-07-08 | 2014-06-30 | Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч | Применение меченых ингибиторов hsp90 |
| EP2972394A4 (en) | 2013-03-15 | 2016-11-02 | Sloan Kettering Inst Cancer | HSP90-DESIGNING AND THERAPY |
| US10071130B2 (en) | 2013-12-12 | 2018-09-11 | The University Of Chicago | Methods and compositions related to Hsp90 inhibitors and breast cancer |
| MX387627B (es) | 2014-09-17 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia |
-
2012
- 2012-07-06 EA EA201490230A patent/EA201490230A1/ru unknown
- 2012-07-06 KR KR1020147003357A patent/KR102025142B1/ko not_active Expired - Fee Related
- 2012-07-06 US US14/131,420 patent/US20140294725A1/en not_active Abandoned
- 2012-07-06 BR BR112014000445A patent/BR112014000445A2/pt not_active Application Discontinuation
- 2012-07-06 JP JP2014520226A patent/JP6054389B2/ja not_active Expired - Fee Related
- 2012-07-06 EP EP12811358.6A patent/EP2729806B1/en active Active
- 2012-07-06 AU AU2012282903A patent/AU2012282903A1/en not_active Abandoned
- 2012-07-06 DK DK12811358.6T patent/DK2729806T3/en active
- 2012-07-06 EP EP17156149.1A patent/EP3208615B1/en active Active
- 2012-07-06 ES ES12811358.6T patent/ES2624982T3/es active Active
- 2012-07-06 EP EP19202091.5A patent/EP3709022A1/en not_active Withdrawn
- 2012-07-06 KR KR1020177009318A patent/KR102138218B1/ko not_active Expired - Fee Related
- 2012-07-06 CA CA2841069A patent/CA2841069C/en not_active Expired - Fee Related
- 2012-07-06 MX MX2014000286A patent/MX347607B/es active IP Right Grant
- 2012-07-06 CN CN201280040632.XA patent/CN104081203B/zh not_active Expired - Fee Related
- 2012-07-06 WO PCT/US2012/045861 patent/WO2013009655A2/en not_active Ceased
- 2012-07-06 AU AU2012282905A patent/AU2012282905B8/en not_active Ceased
- 2012-07-06 US US14/131,423 patent/US9555137B2/en active Active
- 2012-07-06 JP JP2014520227A patent/JP6218147B2/ja not_active Expired - Fee Related
- 2012-07-06 CA CA2841173A patent/CA2841173C/en not_active Expired - Fee Related
- 2012-07-06 CN CN201280040606.7A patent/CN104081206B/zh not_active Expired - Fee Related
- 2012-07-06 MX MX2014000292A patent/MX2014000292A/es unknown
- 2012-07-06 WO PCT/US2012/045864 patent/WO2013009657A1/en not_active Ceased
- 2012-07-06 CN CN201810715481.2A patent/CN109374889B/zh not_active Expired - Fee Related
- 2012-07-06 ES ES17156149T patent/ES2766623T3/es active Active
-
2016
- 2016-11-30 JP JP2016232580A patent/JP6662759B2/ja not_active Expired - Fee Related
-
2017
- 2017-06-27 AU AU2017204369A patent/AU2017204369B2/en not_active Ceased
-
2019
- 2019-07-04 JP JP2019125455A patent/JP2019194232A/ja active Pending
-
2020
- 2020-07-21 US US16/934,881 patent/US11607465B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017121233A5 (enExample) | ||
| US12115146B2 (en) | Treatment of skeletal-related events for breast cancer patients | |
| Schlumberger et al. | ENDOCRINE TUMOURS: approach to the patient with advanced differentiated thyroid cancer | |
| AU2016256470B2 (en) | Methods of treating cancer | |
| JP2016540767A (ja) | 局所進行性又は転移性エストロゲン受容体陽性乳がんの治療のためのエストロゲン受容体調節因子 | |
| JP2019532051A5 (enExample) | ||
| JP2023116537A (ja) | 非小細胞肺がんの治療に使用するためのオシメルチニブ | |
| JP2020505425A (ja) | 癌治療 | |
| JP2020523355A (ja) | 肉腫を処置することへの使用のためのチノスタムスチン | |
| US20140155372A1 (en) | Combinations of akt and mek inhibitor compounds, and methods of use | |
| JP2018521064A5 (enExample) | ||
| JP2015508903A5 (enExample) | ||
| JP2024503718A (ja) | 乳がんを治療するための薬学的組成物及びその使用方法 | |
| JP2008525493A5 (enExample) | ||
| TWI569808B (zh) | 肝細胞腫瘤（ｈｃｃ）之治療 | |
| US20220257552A1 (en) | Methods of prescreening and treating breast cancers with selective androgen receptor modulators | |
| US9566334B2 (en) | Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder | |
| US20210228529A1 (en) | Pharmaceutical compositions for treating breast cancers and methods of uses thereof | |
| JP2014506904A (ja) | γセクレターゼ阻害剤の投与方法 | |
| WO2023174210A1 (en) | Combination treatment for cancer | |
| Butowski | Anti-angiogenic therapy in glioma | |
| WO2025076094A1 (en) | Egfr inhibitors of formula (i) for use in methods of treating cancer having two or more mutations in egfr | |
| Schran et al. | Regular dosing of zoledronic acid maintains continuous suppression of osteolysis in patients with malignant bone disease | |
| Xie et al. | Effects of Arsenic Trioxide on Min Progressive High-Grade Osteosar of the Extremities Metastatic to th Lung: Results of 39 Patients Treat a Single Institution. | |
| Ambady et al. | 2013 WFNO-SNO Abstracts |